...- Wild-type for mutations in EGFR, KRAS and ALK...

...Percentage of Participants With Objective Response`Time to Tumor Progression (TTP)`Duration of Response (DR)`Overall Survival (OS)`Percentage of Participants Surviving at 1 Year`Area Under the Curve From Time Zero to 24 Hours [AUC(0-24)] of Erlotinib`AUC(0-24) of Sunitinib`AUC(0-24) of SU-012662 (Metabolite of Sunitinib)`AUC(0-24) of Total Drug (Sunitinib + SU-012662)`Maximum Observed Plasma Concentration (Cmax) of Erlotinib`Cmax of Sunitinib`Cmax of SU-012662 (Metabolite of Sunitinib)`Cmax of Total Drug (Sunitinib + SU-012662)`Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) for Erlotinib`AUC(0-inf) for Sunitinib`AUC(0-inf) for SU-012662 (Metabolite of Sunitinib)`AUC(0-inf) for Total Drug (Sunitinib + SU-012662)`Plasma Decay Half-life (t1/2) of Erlotinib`Plasma Decay Half-life (t1/2) of Sunitinib`Erlotinib Clearance at Steady State After Oral Administration (CL/F)`Sunitinib Clearance at Steady State After Oral Administration (CL/F)`Time to Reach Maximum Observed Plasma Concentration (Tmax) for Erlotinib`Tmax for Sunitinib`Tmax for SU-012662 (Metabolite of Sunitinib)`Tmax for Total Drug (Sunitinib + SU-012662)`Dose-Corrected Observed Plasma Trough Concentrations (Ctrough) for Erlotinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Dose-Corrected Ctrough for Erlotinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Dose-Corrected Ctrough for Sunitinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Dose-Corrected Ctrough for Sunitinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)`Percentage of Participants With Epidermal Growth Factor Receptor (EGFR) Expression by Immunohistochemistry (IHC) Using 0 Percent [%] Cutoff`PFS in Subgroups That Were Defined by EGFR Expression (Using 0% Cutoff)`Percentage of Participants With EGFR Expression by IHC (Using 10% Cutoff)`PFS in Subgroups That Were Defined by EGFR Expression (Using 10% Cutoff)`Percentage of Participants With EGFR Gene Copy Number Increase`PFS in Subgroups That Were Defined by EGFR Gene Copy Number Increase`Percentage of Participants With EGFR Gene Amplification`PFS in Subgroups That Were Defined by EGFR Gene Amplification`Percentage of Participants With EGFR Gene Mutation`PFS in Subgroups That Were Defined by EGFR Gene Mutation`Percentage of Participants With KRAS (V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog) Gene Mutations`PFS in Subgroups That Were Defined by KRAS Gene Mutation`Percentage of Participants With Germline Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Polymorphisms`PFS in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms`Overall Survival (OS) in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms`Percentage of Participants With Germline Platelet-derived Growth Factor Receptor Beta (PDGFRB) Polymorphisms`PFS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms`OS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms`Percentage of Participants by Tumor VEGFR Mutation`Correlation of Polymorphisms in Stem Cell Factor Receptor (c-Kit), FMS-like Tyrosine Kinase 3 Receptor (FLT-3), and c-FMS With Blood Counts`Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile`PFS in Subgroups That Were Defined by RNA Expression Profile`Health Related Quality of Life (HRQoL) and Lung Cancer Related Symptoms as Assessed With European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score`EORTC-QLQ-C30 Lung Cancer Module (LC13) Score`Number of Participants With Blood Pressure (BP) Greater Than 150/100 Millimeters of Mercury (mmHg)`Number of Participants With BP Greater Than 200/110 mmHg`Number of Participants on Anti-hypertensive Medications`Plasma Concentration of VEGF-C at Baseline`Plasma Concentration of Soluble VEGFR-2 at Baseline`Plasma Concentration of Soluble VEGFR-3 at Baseline`Plasma Concentration of Soluble KIT (sKIT) at Baseline...

...effectiveness of combined ACK1/AKT inhibition on the proliferation, migration, invasion, and apoptosis of KRAS-mutant NSCLC cell lines (NCI-H23, NCI-H358, and A549). The cells were treated with an inhibitor of either ACK1 (dasatinib or sunitinib) or AKT (MK-2206 or GDC-0068)...We showed that combined administration of ACK1 and AKT inhibitors at the optimal concentrations effectively suppressed NSCLC cell viability and promoted apoptosis, while inducing cell cycle arrest at the G2 phase...Collectively, our results demonstrate the promising therapeutic potential of combined ACK1/AKT inhibition as a strategy against KRAS-mutant NSCLC.